浙江滬杭甬(00576.HK):浙商證券獨立董事王寶桐任期屆滿離任
格隆匯 1 月 20日丨浙江滬杭甬(00576.HK)發佈公吿,浙商證券(601878.SH)(以下簡稱“公司”)獨立董事王寶桐先生任期至2021年1月29日屆滿且連任時間達到六年。根據相關規定,獨立董事在上市公司連續任職時間不得超過六年。由於目前公司董事會成員9名,其中獨立董事3名,王寶桐先生離任將導致公司獨立董事人數少於董事會成員三分之一。根據相關規定,王寶桐先生將繼續履行其獨立董事及董事會相關專門委員會委員職責,直至公司選出新的獨立董事。公司將按照有關規定儘快履行相關程序,完成獨立董事的補選工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.